Trade Ideas

Actionable trade ideas with defined risk and time horizons.

Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.

Articles

14,477 total articles

Devon Energy: The Market Still Undervalues the Combined Operator

Devon Energy: The Market Still Undervalues the Combined Operator

Devon has finished integrating Coterra and laid out an aggressive capital-return plan, but the stock is trading below key technicals and well inside a valuation band that doesn't fully reflect $2.4B of free cash flow, $600M in targeted synergies and explicit debt retirement. We think a disciplined long with a clear stop and a realistic target captu…

Victoria's Secret Has Reclaimed Its Identity - Buy the Re-rate

Victoria's Secret Has Reclaimed Its Identity - Buy the Re-rate

Victoria's Secret has stopped trying to be everything to everyone and is once again selling aspirational lingerie and intimate apparel at healthier margins. The stock has room to re-rate as comps stabilize, promotional pressure eases and management monetizes new distribution channels. Enter a tactical long with a clear stop and a medium-term target…

ANI Pharmaceuticals: Buy the Next Chapter, Not the Last Quarter

ANI Pharmaceuticals: Buy the Next Chapter, Not the Last Quarter

ANI Pharmaceuticals (ANIP) looks like a buy for patient traders. The market is focused on recent execution - which has been solid - but may be underpricing the commercial and rare-disease optionality from ILUVIEN and continued rare-disease tailwinds. With a market cap near $1.82B, FCF of $179M and management guiding to north of $1B in revenue for 2…

MNTN: Cash Flow Breakthrough Makes a Playable Re-rate

MNTN: Cash Flow Breakthrough Makes a Playable Re-rate

MNTN looks set to trade higher as operating cash flow catches up with earnings and the company's net-cash balance sheet separates enterprise value from headline market cap. Premium multiples still price growth, but a clear path to stronger free cash generation and several near-term catalysts create a pragmatic trade: enter at $10.30, target $14.00,…

Buy the Pullback: Amkor’s Growth Is Priced for Less Than It Should Be

Buy the Pullback: Amkor’s Growth Is Priced for Less Than It Should Be

Amkor (AMKR) has been a direct beneficiary of the AI-driven bump in packaging and test demand but still trades at reasonable multiples. The company's $1.69B Q1 revenue beat, optimistic Q2 guidance, and a 10-year capacity partnership with TSMC argue for upside. I present a swing trade plan to capture re-rating into $75 while keeping a disciplined st…

Zeta Global: Profitability Arrives — Time to Trade the Re-rating

Zeta Global: Profitability Arrives — Time to Trade the Re-rating

Zeta Global's revenue acceleration and sizable free cash flow have finally begun to show up at the bottom line. With a visible partnership pipeline and recurring revenue tailwinds, the stock looks tradeable on a mid-term horizon. This plan defines an entry, stop and target while laying out catalysts and the key risks that would invalidate the setup…